StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
2389.HK$0.07+0.00%
Fair $0.07+0.0%

2389.HK

Beijing Health (Holdings) Limited

Healthcare / Medical Care FacilitiesHKSE

$0.07

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $0.07Fund rank 30/100 · Data gapFallback financials|
SA 13/F
F-Score: 3/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 33% · confianza 25%

FCF escenarios

weak_data · normalized FCF $-42.2M · quality 72.3/100

Data gap 30/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 37/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

13/100

F

Piotroski

3/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

20/100

SEC 0%

Latest source: yahooPeriods: 5Warnings: 1yahoo: 5
No SEC-backed annual rows; valuation uses fallback financial data. Sector-specific holding-company NAV/SOTP model required: targets are disabled until look-through holdings, debt and discount data exists. ROE is -6.1%, below the 5% threshold
Thesis & Journal · 2389.HKLocal privado en este navegador · Beijing Health (Holdings) Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$406M

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

-6.1%

↓

Gross Margin

27.0%

↓

Debt/Equity

0.07

↓
No hay histórico de precio usable para pintar el gráfico TradingView.

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2021–2025 · 4 años de histórico normalizado

Revenue CAGR

-6.3%

FCF CAGR

—

FCF margin

-21.6%

FCF / Net income

0.34x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $157.2M · net income $-100.9M · FCF $-34.0M

2021-FY → 2025-FY

Gross margin

27.0%+3.9% pts

Operating margin

-33.5%+8.6% pts

Net margin

-64.2%-44.9% pts

FCF margin

-21.6%-10.4% pts
MetricTTM
2025
2024
2023
2022
2021
Income Statement
Revenue$157.2M$157.2M$149.9M$140.3M$166.5M$203.8M
Net Income$-100.9M$-100.9M$-116.2M$-61.9M$-97.7M$-39.4M
EBITDA$-78.3M$-78.3M$-97.5M$-44.2M$-75.2M$-10.4M
EPS——-0.02-0.01-0.02-0.01
Gross Margin27.0%27.0%23.8%27.4%27.9%23.1%
Operating Margin-33.5%-33.5%-38.8%-45.1%-39.2%-42.1%
Net Margin-64.2%-64.2%-77.5%-44.1%-58.7%-19.3%
Balance Sheet
Debt/Equity0.070.070.000.000.020.02
Current Ratio1.261.26————
Cash Flow
Free Cash Flow$-34.0M$-34.0M$-42.2M$-45.1M$-34.4M$-22.8M
Returns
ROE-6.1%-6.1%-6.8%-3.3%-4.8%-1.7%
Valuation
P/B0.240.240.270.210.200.24
Growth & Yield
Revenue Growth4.8%4.8%6.8%-15.7%——
EPS Growth——-90.1%37.3%——

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · available periodreconcilia total n/d
Return attribution requires positive start and end prices.

Unavailable: positive start/end prices are required.